Something old

Metformin
Metformin is the only biguanide used in the UK and US, and it is the most widely prescribed oral antidiabetic therapy worldwide. Its discovery stems from the use of Galega officinalis (goat's rue or French lilac) as a traditional treatment for symptoms of diabetes in medieval Europe [Bailey and Turner, 1996] . G. officinalis is rich in the glucose-lowering substance guanidine from which metformin is derived. Since its introduction for the treatment of type 2 diabetes in the UK in the 1960s and launch in the US in 1995, metformin has been used in several other indications with variable success. The evidence for using metformin for treating various clinical aspects associated with the polycystic ovary syndrome (PCOS) is comprehensively reviewed by Lashan.
Glucocorticoid
Cortisone was first identified by the American chemist Edward Kendall, and he was awarded the 1950 Nobel Prize for Physiology or Medicine with Philip Hench and Tadeus Reichstein for the discovery of adrenal cortex hormones, their structures, and their functions. Cortisone and its various formulations was an instant success in a wide range of diseases, including adrenal insufficiency. However, whilst management of adrenal insufficiency using hydrocortisone (and other formulations) is lifesaving, fine-tuning of therapy has always been a challenge with periods of glucocorticoid overreplacement or under-replacement a norm for most patients.
This balance is probably best illustrated by the late US President John F. Kennedy, who was diagnosed with Addison's disease in the 1940s: Gravely ill, Kennedy was admitted to a London hospital in 1947. His doctor's verdict: 'He hasn't got a year to live' [Gilbert, 2010] .
Despite this rather stark prognosis, Kennedy survived until his untimely death using various formulations of glucocorticoid. During this period he appeared occasionally Cushingoid (reflective of over-replacement), whilst at other times was deeply pigmented (suggesting underreplacement).
More recently, several advances in our understanding of adrenal replacement therapy have occurred (e.g. using smaller daily doses). Chan and Debono review new formulations of hydrocortisone which could result in an even more physiological glucocorticoid replacement regimen.
Propylthiouracil
Thyrotoxicosis is a common endocrine condition that may be secondary to a number of underlying processes. Thyrotoxicosis is the clinical syndrome that results when tissues are exposed to high levels of circulating thyroid hormone. In most instances, thyrotoxicosis is due to hyperactivity of the thyroid gland, or hyperthyroidism [Weetman, 2009] . Graves' disease, an autoimmune thyroid disease associated with TSHreceptor stimulating antibodies, is the most common form of hyperthyroidism. Thyroid storm (also known as thyroid or thyrotoxic crisis) is an uncommon condition reflecting an extreme physiological state within the spectrum of thyrotoxicosis, and is reviewed in the TAE Endocrine and Metabolic Emergencies series by Carroll and Matfin.
Antithyroid drugs (i.e. thionamides) are widely used for the treatment of hyperthyroidism and work by preventing the formation of further thyroid hormone by inhibiting the iodination of tyrosine residues. Metimazole (MMI) or carbimazole (CBZ) are generally the first-line antithyroid drugs chosen, with propylthiouracil (PTU) traditionally preferred in certain situations (such as thyroid storm) because of its more rapid onset of action and the additional benefit of inhibition of peripheral deiodinase enzyme-mediated conversion of thyroxine (T4) to liothyronine (T3).
However, the US Food and Drug Administration (FDA) has recently released an advisory on PTU for its liver toxicity potential (and also increased risk of vasculitis) [Food and Drug Administration, 2010] . Despite PTU being in clinical use since 1947, the full extent of PTU-related druginduced liver injury (DILI) has only recently come to light [Malozowski and Chiesa, 2010] . In the US, PTU has been identified as the third most-frequent cause of DILI requiring liver transplant, and administration can lead to severe DILI and death (especially in children, but also adults) [Rivkees and Szarfman, 2010] . As a consequence, many experts now recommend using either MMI or CBZ in all thyrotoxic patients (unless other compelling reasons exist for using PTU such as pregnancy), and achieving T4 into T3 conversion inhibition solely with beta-blockers and glucocorticoids [Food and Drug Administration, 2010; Malozowski and Chiesa, 2010] .
Something new. . .
Non alcoholic fatty liver disease
Non alcoholic fatty liver disease (NAFLD) and its complications have emerged in the last few decades as a leading clinical and public health challenge. Uncertainties in the diagnosis, monitoring, and treatment of NAFLD (and its complications nonalcoholic steatohepatitis [NASH], cirrhosis, liver failure, and hepatocellular carcinoma) result in clinicians facing major dilemmas about patient management. Many of these issues regarding NAFLD and its associations (including other aspects of the metabolic syndrome) are addressed by Mehta.
Other new and exciting therapeutic advances will be covered in future TAE issues. Examples include the explorative role of antisense therapy in metabolic disorders (e.g. hypercholestrolemia); and how vaccines may prevent type 1 diabetes. Any other suggestions for reviews, or submission of original or review articles are welcome and should be directed to the TAE editorial team.
